Ascendia

  MARKET NEWS

Vaxxinity Announces Collaboration on Space Medicine Research With University of Central Florida
Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis & Treatment of Cancer & Other Diseases
XOMA Expands its Commercial Royalty & Milestone Portfolio With DSUVIA Acquisition
Vivtex & AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies for Inflammatory Diseases
Orphan Drug Designation Granted to PTX-252 by FDA for the Treatment of Acute Myeloid Leukaemia
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients With Glioblastoma Multiforme

  FEATURED EDITORIAL

  COMPANY PROFILE

Phosphorex, a leading CDMO located just 26.2 miles from Boston in Hopkinton, MA. Our state-of-the-art facility spans at 30,000 Sq. Ft., with an additional 12,000 Sq. Ft. of cGMP space set to come online in 2024. With our expertise and innovative technologies, we excel in encapsulating drugs into microspheres or nanoparticles, enabling targeted delivery, protection of therapeutic agents, controlled release, and improved bioavailability. From proof-of-concept to clinical studies, our integrated solution supports all phases of formulation development. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Kindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development & Manufacturing Organization

Kindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development & Manufacturing Organization

Kindeva Drug Delivery recently announced it has acquired Summit Biosciences Inc., an intranasal drug delivery contract development and manufacturing organization, from its founding….

Credence MedSystems Announces a Significant Milestone Toward Scaling Manufacturing Capabilties

Credence MedSystems Announces a Significant Milestone Toward Scaling Manufacturing Capabilties

Credence MedSystems recently announced it has successfully completed Factory Acceptance Testing (FAT) for production of its Companion® injection device platform on the company’s new Clinical Assembly Line…..

Bora Pharmaceuticals to Acquire US Pharma Manufacturer Upsher-Smith for 0 Million in Transaction to Fuel Global Expansion

Bora Pharmaceuticals to Acquire US Pharma Manufacturer Upsher-Smith for $210 Million in Transaction to Fuel Global Expansion

Bora Pharmaceuticals Co., Ltd. recently announced its Board of Directors has approved the acquisition of Upsher-Smith Laboratories, Inc., a generics manufacturer based in Minnesota, US, from shareholders, Sawai….

Abzena Launches AbZelect Platforms for Improving Cell Line Development Efficiency on the Pathway to IND

Abzena Launches AbZelect Platforms for Improving Cell Line Development Efficiency on the Pathway to IND

Abzena has launched AbZelect and AbZelectPRO cell line development (CLD) platforms for accelerating the generation of production cell lines for manufacture of antibodies and recombinant proteins. The platforms will….

  WHITEPAPERS & WEBINARS

WEBINAR - 2024 Trends in Topical Drug Delivery: Insights & Innovation

WEBINAR - 2024 Trends in Topical Drug Delivery: Insights & Innovation

This webinar will discuss some of the key trends from these leaders in the topical market on both a global and regional level, including the increased importance of sensory properties and the rise in non-conventional product formats, among others…..

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

In this webinar you will learn how digital chemistry tools facilitate rapid screening of formulation parameters, aiding in the identification of optimal drug delivery systems, excipient selection, and dosage forms….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Monitoring Low Dose API Blend Uniformity With Parteck® M Mannitol Using Near-Infrared (NIR) Spectroscopy

WHITEPAPER - Monitoring Low Dose API Blend Uniformity With Parteck® M Mannitol Using Near-Infrared (NIR) Spectroscopy

Direct compression is often used for tablet manufacturing because it is the shortest, most effective, and least complex method. The physical properties of active pharmaceutical ingredients (APIs) can, however, create a challenge for flowability and compressibility, and, as a result, …

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

This white paper evaluates the viscosity-reducing capacities of excipients and excipient combinations. It shows the over-additive effect of using two excipients together and addresses how excipients’ viscosity-reducing ability depends on pH. The results show the effect of protein viscosity on …

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

Early-stage development is critical to shortening your product’s timelines while establishing a solid foundation for clinical trials. In this insightful article from Dr. Srinivasan Shanmugam, Adare’s Executive Director of Pharmaceutical Sciences, learn what’s needed to make your product’s early-stage development …

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 31 – Analytical Testing
February 7 – Injection Devices